Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?

Pediatr Nephrol. 2014 Mar;29(3):329-32. doi: 10.1007/s00467-013-2722-2. Epub 2013 Dec 22.

Abstract

Patients with end-stage renal disease (ESRD) due to atypical HUS (aHUS) now have several potential options that can enable successful kidney transplantation. This editorial addresses these options by considering key factors that are important when making an individual treatment decision.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Atypical Hemolytic Uremic Syndrome
  • Complement Factor H / deficiency*
  • Complement Factor H / genetics
  • Female
  • Hemolytic-Uremic Syndrome / surgery*
  • Hereditary Complement Deficiency Diseases
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Diseases / complications*
  • Kidney Transplantation*
  • Liver Transplantation*
  • Mutation*
  • Plasma Exchange*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • complement factor H, human
  • Complement Factor H
  • eculizumab

Supplementary concepts

  • Complement Factor H Deficiency